Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3843
Peer-review started: November 25, 2014
First decision: December 26, 2014
Revised: January 2, 2015
Accepted: February 5, 2015
Article in press: February 5, 2015
Published online: April 7, 2015
Core tip: Sorafenib is the standard of treatment for advanced hepatocellular carcinoma (HCC). However, the suitability of sorafenib is limited by its low response rates, and unsuitability for patients with poor liver function. Therefore, other treatment modalities are required. Hepatic arterial infusion chemotherapy (HAIC) has the advantages of delivering high levels of chemotherapeutic drugs directly into tumor-associated hepatic arterial branches and repeat injections are relatively simple to carry out. Thus the local therapeutic level is increased and systemic adverse effects are decreased. In the future, HAIC may be a promising treatment strategy for the management of advanced HCC.